TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Ulcerative Colitis (UC)
Brief Summary: The purpose of this study is to determine whether BMS-936557 is effective in the treatment of moderate to severely active ulcerative colitis in patients who have had insufficient response and/or intolerance to other medical therapy for ulcerative colitis


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: abatacept | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: abatacept; Type: OTHER; Interventions: Drug: abatacept | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): abatacept
B: Arm Label: Cohort 1: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Cohort 2: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Cohort 3: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Open Label; Type: OTHER; Interventions: Drug: Anti-IP-10 Antibody | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Induction, Cohort 2: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Cohort 1: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Cohort 2: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Open Label
C: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
D: Arm Label: rhuMAb Beta7; Type: EXPERIMENTAL; Interventions: Drug: rhuMAb Beta7 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: rhuMAb Beta7; Assigned to Arm(s): rhuMAb Beta7

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Survey of Osteoarthritis Real World Therapies (SORT)
Brief Summary: This was a study to estimate the proportion of participants with osteoarthritis of the knee(s) who were treated with oral or topical analgesics for their symptoms, who did and did not report adequate pain relief at Baseline and to characterize their pain level over a 12-month follow-up period.


Options:
A: Arm Label: All Enrolled Participants; Type: N/A; Interventions: Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s) | Intervention Type: DRUG; Name: Standard of care for treatment of osteoarthritis (OA) of knee(s); Assigned to Arm(s): All Enrolled Participants
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D
D: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Survey of Osteoarthritis Real World Therapies (SORT)
Brief Summary: This was a study to estimate the proportion of participants with osteoarthritis of the knee(s) who were treated with oral or topical analgesics for their symptoms, who did and did not report adequate pain relief at Baseline and to characterize their pain level over a 12-month follow-up period.


Options:
A: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: All Enrolled Participants; Type: N/A; Interventions: Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s) | Intervention Type: DRUG; Name: Standard of care for treatment of osteoarthritis (OA) of knee(s); Assigned to Arm(s): All Enrolled Participants
D: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Survey of Osteoarthritis Real World Therapies (SORT)
Brief Summary: This was a study to estimate the proportion of participants with osteoarthritis of the knee(s) who were treated with oral or topical analgesics for their symptoms, who did and did not report adequate pain relief at Baseline and to characterize their pain level over a 12-month follow-up period.


Options:
A: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: All Enrolled Participants; Type: N/A; Interventions: Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s) | Intervention Type: DRUG; Name: Standard of care for treatment of osteoarthritis (OA) of knee(s); Assigned to Arm(s): All Enrolled Participants
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Survey of Osteoarthritis Real World Therapies (SORT)
Brief Summary: This was a study to estimate the proportion of participants with osteoarthritis of the knee(s) who were treated with oral or topical analgesics for their symptoms, who did and did not report adequate pain relief at Baseline and to characterize their pain level over a 12-month follow-up period.


Options:
A: Arm Label: radiofrequency group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: radiofrequency | Arm Label: conventional group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol (conventional), Drug: Ketorolac Tromethamine (conventional) | Intervention Type: PROCEDURE; Name: radiofrequency; Assigned to Arm(s): radiofrequency group | Intervention Type: DRUG; Name: Paracetamol (conventional); Assigned to Arm(s): conventional group | Intervention Type: DRUG; Name: Ketorolac Tromethamine (conventional); Assigned to Arm(s): conventional group
B: Arm Label: Cooled radiofrequency; Type: EXPERIMENTAL; Interventions: Device: Cooled Radiofrequency | Arm Label: Corticosteroid injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: Corticosteroid injection | Intervention Type: DEVICE; Name: Cooled Radiofrequency; Assigned to Arm(s): Cooled radiofrequency | Intervention Type: DRUG; Name: Corticosteroid injection; Assigned to Arm(s): Corticosteroid injection
C: Arm Label: All Enrolled Participants; Type: N/A; Interventions: Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s) | Intervention Type: DRUG; Name: Standard of care for treatment of osteoarthritis (OA) of knee(s); Assigned to Arm(s): All Enrolled Participants
D: Arm Label: Conventional Radiofrequency of the genicular nerves; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Radiofrequency ablation of the genicular nerves | Arm Label: Cooled Radiofrequency of the genicular nerves; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cooled Radiofrequency ablation of the genicular nerves | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: PROCEDURE; Name: Conventional Radiofrequency ablation of the genicular nerves; Assigned to Arm(s): Conventional Radiofrequency of the genicular nerves | Intervention Type: PROCEDURE; Name: Cooled Radiofrequency ablation of the genicular nerves; Assigned to Arm(s): Cooled Radiofrequency of the genicular nerves | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham procedure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Blinded, Double Dummy, Multi-center, Placebo Controlled, 3 Period, Crossover Study to Assess the Effect of QVA149 (110/50 µg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control.
Brief Summary: This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149) on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).


Options:
A: Arm Label: Tiotropium + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium bromide, Drug: Placebo Salmeterol | Arm Label: Salmeterol + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Placebo Tiotropium | Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol + Placebo | Intervention Type: DRUG; Name: Placebo Salmeterol; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Placebo Tiotropium; Assigned to Arm(s): Salmeterol + Placebo
B: Arm Label: GSK573719/GW642444 125/25; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 125/25 | Arm Label: GSK573719/GW642444 62.5/25; Type: EXPERIMENTAL; Interventions: Drug: GSK573719/GW642444 62.5/25 | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Arm Label: tiotropium bromide; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium bromide | Intervention Type: DRUG; Name: GSK573719/GW642444 125/25; Assigned to Arm(s): GSK573719/GW642444 125/25 | Intervention Type: DRUG; Name: GSK573719/GW642444 62.5/25; Assigned to Arm(s): GSK573719/GW642444 62.5/25 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: tiotropium bromide; Assigned to Arm(s): tiotropium bromide
C: Arm Label: indacaterol and glycopyrronium bromide (QVA149); Type: EXPERIMENTAL; Interventions: Drug: indacaterol and glycopyrronium bromide (QVA149) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium | Intervention Type: DRUG; Name: indacaterol and glycopyrronium bromide (QVA149); Assigned to Arm(s): indacaterol and glycopyrronium bromide (QVA149) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Assigned to Arm(s): Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised-controlled Trial of Switching to Alternative Tumour-necrosis Factor (TNF)-Blocking Drugs or Abatacept or Rituximab in Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug
Brief Summary: The principal aim of this study is to fill a clear knowledge gap and provide guidance for rheumatologists and reassurance to the patient group on a management challenge faced daily in rheumatology practice. Specifically, it aims to provide robust evidence on the optimal management of patients with established RA that have failed an anti-TNF therapy (the first of the biological therapies to be introduced); in particular, the investigators wish to address whether the currently licensed but non NICE-approved treatment options, TNF-blocking drug or abatacept, are equivalent to the NICE-approved treatment, rituximab. If so, the intention is to broaden treatment options and target these specific therapies to disease sub-groups.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cimzia; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Cimzia
B: Arm Label: CDP870 100mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 100mg | Arm Label: CDP870 200mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 200mg | Arm Label: CDP870 400mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 400mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of CDP870 | Intervention Type: DRUG; Name: CDP870 400mg; Assigned to Arm(s): CDP870 400mg | Intervention Type: DRUG; Name: CDP870 200mg; Assigned to Arm(s): CDP870 200mg | Intervention Type: DRUG; Name: CDP870 100mg; Assigned to Arm(s): CDP870 100mg | Intervention Type: DRUG; Name: Placebo of CDP870; Assigned to Arm(s): Placebo
C: Arm Label: TNF-blocking drug; Type: EXPERIMENTAL; Interventions: Drug: Etanercept, Drug: Adalimumab, Drug: Certolizumab Pegol, Drug: Infliximab, Drug: Golimumab | Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Arm Label: Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rituximab | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): TNF-blocking drug
D: Intervention Type: DRUG; Name: Certolizumab pegol (CDP870); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet-based Physical Activity Intervention
Brief Summary: The purpose of this study is to determine whether access to a website with personalized feedback on physical activity level and suggestions to increase physical activity results in improvements in self-reported physical activity, anthropometrics and physiological measurements


Options:
A: Arm Label: Cognitive app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford | Arm Label: Social app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford | Arm Label: Affect app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford | Arm Label: Nutrition app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford | Intervention Type: BEHAVIORAL; Name: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford; Assigned to Arm(s): Affect app, Cognitive app, Nutrition app, Social app
B: Arm Label: Exercise programme only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SMS reminder; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise programme plus SMS reminders | Intervention Type: BEHAVIORAL; Name: Exercise programme plus SMS reminders; Assigned to Arm(s): SMS reminder
C: Arm Label: I-STAND; Type: EXPERIMENTAL; Interventions: Behavioral: I-STAND | Arm Label: Healthy Living; Type: ACTIVE_COMPARATOR; Interventions: Other: Healthy Living | Intervention Type: BEHAVIORAL; Name: I-STAND; Assigned to Arm(s): I-STAND | Intervention Type: OTHER; Name: Healthy Living; Assigned to Arm(s): Healthy Living
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: Behavioral: website assess | Intervention Type: BEHAVIORAL; Name: website assess; Assigned to Arm(s): Control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sugar Sweetened Beverages And Cardiovascular Disease Risk
Brief Summary: The overall aim of the study is to compare the effects of three types of beverages - sugar-sweetened (SSB), artificially sweetened (ASB), and unsweetened (USB) - on cardiovascular disease (CVD) risk factors and body weight among young adults.


Options:
A: Arm Label: DIPI: Danish national dietary guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: DIPI: Specific IHD dietary guideline; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: Normal dietary habits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: DIPI; Assigned to Arm(s): DIPI: Danish national dietary guidelines, DIPI: Specific IHD dietary guideline
B: Arm Label: Sucrose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Sucrose | Arm Label: Aspartame; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Aspartame | Intervention Type: DIETARY_SUPPLEMENT; Name: Sucrose; Assigned to Arm(s): Sucrose | Intervention Type: DIETARY_SUPPLEMENT; Name: Aspartame; Assigned to Arm(s): Aspartame
C: Arm Label: Vegan Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention Meetings, Behavioral: Physical Activity, Behavioral: Podcasts/Mailings | Arm Label: Omnivorous (Omni) Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention Meetings, Behavioral: Physical Activity, Behavioral: Podcasts/Mailings | Intervention Type: BEHAVIORAL; Name: Dietary Intervention Meetings; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet | Intervention Type: BEHAVIORAL; Name: Podcasts/Mailings; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet
D: Arm Label: Sugar-Sweetened Beverages; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Provision of beverages | Arm Label: Artificially-sweetened Beverages; Type: EXPERIMENTAL; Interventions: Behavioral: Provision of beverages | Arm Label: Unsweetened Beverages; Type: EXPERIMENTAL; Interventions: Behavioral: Provision of beverages | Intervention Type: BEHAVIORAL; Name: Provision of beverages; Assigned to Arm(s): Artificially-sweetened Beverages, Sugar-Sweetened Beverages, Unsweetened Beverages

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Perioperative Effect of Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response
Brief Summary: To observe the effect of glucocorticoid on the dynamic changes of monocyte subsets in the peripheral blood of valve disease patients undergoing cardiopulmonary bypass perioperatively.


Options:
A: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone, Placebo
B: Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar pill
C: Arm Label: Corticosteroid; Type: EXPERIMENTAL; Interventions: Drug: Corticosteroid | Intervention Type: DRUG; Name: Corticosteroid; Assigned to Arm(s): Corticosteroid
D: Arm Label: Study (CytoSorb); Type: EXPERIMENTAL; Interventions: Device: CytoSorb | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Corticosteroid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone | Intervention Type: DEVICE; Name: CytoSorb; Assigned to Arm(s): Study (CytoSorb) | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Corticosteroid

Answer: C